BACKGROUND: Resveratrol shows chemopreventive and other biological affects in in vitro and some animal studies. The bioactivities of resveratrol may be attributed to qualitative and quantitative differences in its cell-type-specific interaction and binding with its cellular targets, denoted as resveratrol targeting proteins (RTPs). MATERIALS AND METHODS: To isolate RTPs, resveratrol was linked to epoxy-activated agarose generating an affinity platform to allow the isolation, purification, and characterization of distinct RTPs from cultured prostate cancer cell extracts. RESULTS: Glutathione sulfotransferase-pi (GSTP1) and estrogen receptor-beta (ER-beta) were found to be new RTPs. Resveratrol affinity chromatography was shown to be an easy method for analyzing resveratrol-responsive protein changes in the androgen-dependent LNCaP cells. CONCLUSION: Resveratrol affects cellular functions at multiple levels, ranging from interaction with detoxification enzymes, such as GSTP1 and transcription by targeting factors such as ER-beta.
BACKGROUND:Resveratrol shows chemopreventive and other biological affects in in vitro and some animal studies. The bioactivities of resveratrol may be attributed to qualitative and quantitative differences in its cell-type-specific interaction and binding with its cellular targets, denoted as resveratrol targeting proteins (RTPs). MATERIALS AND METHODS: To isolate RTPs, resveratrol was linked to epoxy-activated agarose generating an affinity platform to allow the isolation, purification, and characterization of distinct RTPs from cultured prostate cancer cell extracts. RESULTS: Glutathione sulfotransferase-pi (GSTP1) and estrogen receptor-beta (ER-beta) were found to be new RTPs. Resveratrol affinity chromatography was shown to be an easy method for analyzing resveratrol-responsive protein changes in the androgen-dependent LNCaP cells. CONCLUSION:Resveratrol affects cellular functions at multiple levels, ranging from interaction with detoxification enzymes, such as GSTP1 and transcription by targeting factors such as ER-beta.
Authors: X Lin; K Asgari; M J Putzi; W R Gage; X Yu; B S Cornblatt; A Kumar; S Piantadosi; T L DeWeese; A M De Marzo; W G Nelson Journal: Cancer Res Date: 2001-12-15 Impact factor: 12.701
Authors: X Lin; M Tascilar; W H Lee; W J Vles; B H Lee; R Veeraswamy; K Asgari; D Freije; B van Rees; W R Gage; G S Bova; W B Isaacs; J D Brooks; T L DeWeese; A M De Marzo; W G Nelson Journal: Am J Pathol Date: 2001-11 Impact factor: 4.307
Authors: Hung-Yun Lin; Ai Shih; Faith B Davis; Heng-Yuan Tang; Leon J Martino; James A Bennett; Paul J Davis Journal: J Urol Date: 2002-08 Impact factor: 7.450
Authors: Justin Lucas; Tze-Chen Hsieh; H Dorota Halicka; Zbigniew Darzynkiewicz; Joseph M Wu Journal: Int J Oncol Date: 2018-08-01 Impact factor: 5.650
Authors: Violetta Krajka-Kuźniak; Hanna Szaefer; Tomasz Stefański; Stanisław Sobiak; Michał Cichocki; Wanda Baer-Dubowska Journal: Cell Mol Biol Lett Date: 2014-08-29 Impact factor: 5.787